PCR Technologies Market by Technology (Conventional, qPCR, dPCR), Product (Instrument, Reagents, Software), Application (Genotyping, Sequencing, Gene expression, diagnostics), Enduser (Academia, pharma-biotech, applied)-Global Forecast to 2025
[193 Pages Report] The global PCR technologies market size was valued at USD 7.2 billion in 2020 and is expected to grow at a compound annual growth rate (CAGR) of 6.3% from 2020 to 2025. The growth PCR technologies market is primarily driven by the rising incidences of target diseases and genetic disorders; continuous technological advancements in PCR technologies, the development of miniaturized portable instruments, and incorporation of robotics; increasing investments, funds, and grants for research activities; increasing use of biomarker profiling for disease diagnostics; and the successful completion of the Human Genome Project.
To know about the assumptions considered for the study, Request for Free Sample Report
COVID-19 Impact on global PCR technologies market
The PCR technologies market, amid the COVID-19 pandemic, experienced positive growth in terms of COVID-19 testing due to the positioning of PCR as the gold standard for genomic sequencing/identification (and hence is the preferred choice for screening). This resulted in significant industry focus towards the early commercialization of PCR-based COVID-19 diagnostic tools. Around 100 major PCR-based COVID-19 screening products were commercialized worldwide till September 2020. However, since PCR is also a preferred technique for cancer screening, its demand in cancer screening applications reported a sharp decline in Q1 & Q2 2020, owing to restricted public movements and de-prioritization of non-essential medical services by respective governments worldwide.
PCR Technologies Market Dynamics
Driver: Rising incidence of target infectious diseases and genetic disorders
The demand for genomic analysis techniques has grown steadily during the last decade on the back of their increasing use (microbial identification and detection of genetic mutations) in the diagnosis of major infectious diseases (such as HIV, tuberculosis, malaria, hepatitis, and Staph-related diseases) and genetic disorders (such as cancer and fragile X syndrome). Growth in the prevalence of target diseases globally, coupled with the proven efficacy of PCR analysis in the diagnosis and estimation of disease-causing microbes, will boost the use of clinical diagnostic tests (including qPCR and dPCR analysis) and support market growth.
Restraint: High costs associated with dPCR instruments
A typical PCR analysis conducted through dPCR instruments involves several scientific technologies (PCR, microfluidics, and nanofabrication) integrated to achieve the desired process outcome. These instruments are small and boast reduced cycle times. However, the development of such instruments requires large capital investments and extensive scientific validation on a nanoscale level. Moreover, dPCR is a relatively new technology; as a result, most manufacturers often price their state-of-the-art dPCR instruments at a premium (~USD 120,000) compared to qPCR instruments (~USD 50,000). For instance, as of January 2018, the average price of a dPCR instrument is reported to be USD 55,000–120,000, based on the device architecture and target application areas in the US. Such high prices have resulted in the subdued adoption of dPCR instruments among price-sensitive end users.
Opportunity: Growing market penetration in emerging countries
Emerging markets are expected to offer significant growth opportunities, led by the rising incidence of infectious and chronic diseases, as well as increasing R&D initiatives to develop innovative genomic techniques such as PCR. Growth will be supported by the expansion of healthcare infrastructure, increase in healthcare expenditure, and reducing procedural costs for qPCR-based and dPCR-based disease diagnosis in emerging countries. Emerging countries are witnessing rapid modernization in healthcare facilities and the expansion of healthcare infrastructure. This factor is contributing to the growing demand for clinical diagnostic procedures among diagnostic laboratories, which is resulting in the increased sales of clinical PCR products.
Challenges: Adoption and implementation of MIQE guidelines
Currently, the use of PCR techniques is unregulated globally, which has made end users reluctant to use PCR products in genomic analysis and disease diagnosis. This is mainly due to a non-uniform consensus that exists for the method by which qPCR/dPCR experiments should be conducted to obtain quality results in a time-bound manner. However, there have been attempts to develop guidelines that can streamline and define the minimum requirements needed to carry a PCR-based genomic procedure in a scientific manner with efficient data generation and interpretation. In this regard, the Minimum Information for the Publication of Quantitative Real-time PCR Experiments (MIQE) guidelines were published in the Journal of Clinical Chemistry (April 2009). This included directions for researchers to develop a robust qPCR-based experiment and the evaluation of generated data.
dPCR technique to show the highest growth in the PCR technologies market during the forecast period
The dPCR segment is expected to grow at the highest CAGR in the PCR technologies market. This is due to ongoing technological developments, growing adoption of dPCR products among key end users (compared with qPCR and other PCR products) across mature markets, continued expansion in the distribution networks of major product manufacturers, and growing private funding for developing and commercializing innovative dPCR instruments. Furthermore, dPCR has many potential applications, including the detection and quantification of low-level pathogens, rare genetic sequences, copy number variations (CNVs), and relative gene expression in single cells are also key factors fuelling the demand growth of dPCR instruments among end users.
By end user, hospitals and diagnostic labs hold the largest market share
The hospitals and diagnostic labs segment account for the largest share of the PCR technologies market. Factors such as the increasing market availability of qPCR reagents in clinical diagnostic applications; ongoing expansion of healthcare infrastructure across emerging countries; high prevalence & incidence of target diseases; and growing awareness are driving the growth of this market segment.
Asia Pacific is expected to grow at the highest CAGR in the PCR technologies market during the forecast period
North America is expected to account for the largest share in the global PCR technologies market in 2020. However, healthcare infrastructure modernization, increasing penetration of cutting-edge diagnostic technologies (including PCR technologies) for research and clinical applications, growing awareness among physicians and healthcare professionals about the benefits of gene-based disease diagnosis and treatment, and the increasing public-private support to develop novel PCR technologies in Asia Pacific countries have accounted for a particularly high growth rate in this region.
To know about the assumptions considered for the study, download the pdf brochure
Key Market Players
As of 2019, the PCR technologies market is dominated by Thermo Fisher Scientific, Inc. (US), F. Hoffman-La Roche Ltd. (Switzerland), Bio-Rad Laboratories, Inc. (US), QIAGEN N.V. (Germany), and Takara Bio, Inc. (Japan). Other prominent players in the market include Agilent Technologies, Inc. (US), bioMérieux S.A. (France), Fluidigm Corporation (US), Danaher Corporation (US), Abbott Laboratories (US), Merck KGaA (Germany), Becton Dickinson and Company (US), Promega Corporation (US), Eppendorf AG (Germany), and Analytik Jena AG (Germany).
F. Hoffmann-La Roche (Switzerland) is a pioneer in the field of life science and biotechnology-based research products and one of the leading market players in the diagnostics industry. The company’s Diagnostics business division operates in the PCR technologies market. The company has a diverse molecular diagnostics product portfolio and a strong geographic presence in more than 100 countries across the world. Roche focuses mainly on product development and commercialization to strengthen its position in the PCR technologies market. The company has launched several products and secured marketing approvals from various authorities during 2017–2020, including the cobas plasma separation card (2018), cobas HPV assay kit (2017), cobas MRSA/SA nucleic acid test kit in European countries (2017), and cobas Liat PCR System (2017). Roche also focuses on partnerships to expand its market reach and improve its distribution capabilities.
Get online access to the report on the World's First Market Intelligence Cloud
- Easy to Download Historical Data & Forecast Numbers
- Company Analysis Dashboard for high growth potential opportunities
- Research Analyst Access for customization & queries
- Competitor Analysis with Interactive dashboard
- Latest News, Updates & Trend analysis
Request Sample Scope of the Report
Get online access to the report on the World's First Market Intelligence Cloud
- Easy to Download Historical Data & Forecast Numbers
- Company Analysis Dashboard for high growth potential opportunities
- Research Analyst Access for customization & queries
- Competitor Analysis with Interactive dashboard
- Latest News, Updates & Trend analysis
|
Report Metric |
Details |
|
Market Size Available for Years |
2018–2025 |
|
Base Year Considered |
2019 |
|
Forecast Period |
2020–2025 |
|
Forecast Units |
Value (USD Billion) |
|
Segments Covered |
Technique, Product, Application, End User, and Region |
|
Geographies Covered |
North America (US & Canada), Europe (Germany, the UK, France, Italy, Spain, and RoE), APAC (Japan, China, India, and the RoAPAC), LATAM (Brazil, Mexico, and RoLATAM), and MEA |
|
Companies Covered |
The major players in the market include Thermo Fisher Scientific, Inc. (US), F. Hoffman-La Roche Ltd. (Switzerland), Bio-Rad Laboratories, Inc. (US), QIAGEN N.V. (Germany), Takara Bio, Inc. (Japan), Agilent Technologies, Inc. (US), bioMérieux S.A. (France), Fluidigm Corporation (US), Danaher Corporation (US), Abbott Laboratories (US), Merck KGaA (Germany), Becton Dickinson and Company (US), Promega Corporation (US), Eppendorf AG (Germany), and Analytik Jena AG (Germany). |
This research report categorizes the PCR technologies market based on technique, product, application, end user, and region.
PCR technologies Market, by Technique
- Conventional PCR
- Real-time PCR (qPCR)
- Digital PCR (dPCR)
- Reverse Transcription PCR (RT-PCR)
- Hot-start PCR
- Multiplex PCR
- Other PCR
PCR technologies Market, by Product
- Instruments
- Reagents and consumables
- Software and services
PCR technologies Market, by Application
- Gene expression analysis
- Genetic sequencing
- Genotyping
- Nucleic acid detection
- Nucleic acid synthesis
- Standard validation/verification
- Diagnostic Applications
- Environmental Applications
- Other Applications
PCR technologies Market, by End User
- Hospitals and diagnostic labs
- Healthcare industry
- Academia and government organizations
- Pharma-biotech companies
- Applied industries
- Other end users
PCR technologies Market, by Region
- North America
- US
- Canada
- Europe
- Germany
- France
- UK
- Italy
- Spain
- RoE
- Asia Pacific
- Japan
- China
- India
- Australia
- South Korea
- RoAPAC
- Latin America
- Brazil
- Mexico
- RoLATAM
- Middle East and Africa
Recent Developments:
- In 2020, Roche (Switzerland) announced FDA 510(k) clearance for the cobas BKV Test on the cobas 6800 and 8800 Systems
- In 2020, Roche (Switzerland) that the cobas SARS-CoV-2 & Influenza A/B Test received emergency use authorization for use on the cobas 6800/8800 Systems from the FDA
- In 2020, Roche (Switzerland) acquired Stratos Genomics (US), an early-stage sequencing technology company, to advance the development of Roche’s nanopore sequencer
Frequently Asked Questions (FAQ):
What are the drivers for the PCR technologies market?
The growth of the market is primarily driven by the rising incidences of target infectious diseases and genetic disorders, increasing financial support for research, and the increasing use of biomarker profiling in disease diagnostics. Companies in the PCR technologies market are focusing on novel product development (including lab-on-chip devices, miniaturized devices, and microfluidics-based instruments) to cater to the growing end-user demand for technologically advanced PCR technologies products.
Which segment provides the most opportunity for growth?
dPCR in the PCR technique segment is expected to show the most opportunity for growth with the highest CAGR in the segment
Who are the leading vendors operating in this market?
Thermo Fisher Scientific, Inc. (US), F. Hoffman-La Roche Ltd. (Switzerland), Bio-Rad Laboratories, Inc. (US), QIAGEN N.V. (Germany), and Takara Bio, Inc. (Japan).
Which region is expected to witness significant demand for PCR technologies in the coming years?
The Asia Pacific is the fastest-growing geographic segment owing to healthcare infrastructure modernization, increasing penetration of cutting-edge diagnostic technologies (including PCR technologies) for research and clinical applications, growing awareness among physicians and healthcare professionals about the benefits of gene-based disease diagnosis and treatment, and the increasing public-private support to develop novel PCR technologies.
What is the COVID 19 impact on PCR technologies in the coming years?
The PCR technologies market, amid the COVID-19 pandemic, experienced positive growth in terms of COVID-19 testing due to the positioning of PCR as the gold standard for genomic sequencing/identification (and hence is the preferred choice for screening). This resulted in significant industry focus towards the early commercialization of PCR-based COVID-19 diagnostic tools. Around 100 major PCR-based COVID-19 screening products were commercialized worldwide till September 2020. However, since PCR is also a preferred technique for cancer screening, its demand in cancer screening applications reported a sharp decline in Q1 & Q2 2020, owing to restricted public movements and de-prioritization of non-essential medical services by respective governments worldwide. .
To speak to our analyst for a discussion on the above findings, click Speak to Analyst
TABLE OF CONTENTS
1 INTRODUCTION (Page No. - 18)
1.1 OBJECTIVES OF THE STUDY
1.2 MARKET DEFINITION
1.2.1 INCLUSIONS & EXCLUSIONS
1.3 STUDY SCOPE
1.3.1 MARKETS COVERED
1.3.2 YEARS CONSIDERED FOR THE STUDY
1.4 CURRENCY USED FOR THE STUDY
1.5 MARKET STAKEHOLDERS
2 RESEARCH METHODOLOGY (Page No. - 21)
2.1 RESEARCH DATA
2.1.1 SECONDARY DATA
2.1.1.1 Key data from secondary sources
2.1.2 PRIMARY DATA
2.2 MARKET ESTIMATION METHODOLOGY
2.2.1 REVENUE MAPPING-BASED MARKET ESTIMATION
2.2.2 USAGE-BASED MARKET ESTIMATION
2.2.3 PRIMARY RESEARCH VALIDATION
2.3 DATA TRIANGULATION
2.4 RESEARCH ASSUMPTIONS
2.5 RESEARCH LIMITATIONS
3 EXECUTIVE SUMMARY (Page No. - 29)
4 PREMIUM INSIGHTS (Page No. - 32)
4.1 PCR TECHNOLOGIES MARKET OVERVIEW
4.2 PCR TECHNOLOGIES MARKET SHARE, BY TECHNIQUE, 2020 VS. 2025
4.3 PCR TECHNOLOGIES MARKET, BY APPLICATION, 2020 VS. 2025 (USD MILLION)
4.4 PCR TECHNOLOGIES MARKET, BY REGION, 2020–2025
5 MARKET OVERVIEW (Page No. - 36)
5.1 INTRODUCTION
5.2 MARKET DYNAMICS
5.2.1 KEY MARKET DRIVERS
5.2.1.1 Rising incidence of target infectious diseases and genetic disorders
5.2.1.2 Continuous advancements in PCR technologies
5.2.1.3 Increasing investments, funds, and grants
5.2.1.4 Increasing use of biomarker profiling for disease diagnostics
5.2.1.5 Successful completion of the human genome project
5.2.2 KEY MARKET RESTRAINTS
5.2.2.1 High device costs associated with dPCR
5.2.2.2 Technical limitations of qPCR and dPCR
5.2.3 KEY MARKET OPPORTUNITIES
5.2.3.1 Growing market penetration in emerging countries
5.2.3.2 Shift from plant-derived to genome-based drug discovery
5.2.4 KEY MARKET CHALLENGES
5.2.4.1 Adoption and implementation of MIQE guidelines
5.2.5 KEY MARKET TRENDS
5.2.5.1 Development of compact, portable, and lab-on-chip PCR devices
5.2.5.2 Ongoing technological integration with the PCR process
5.3 INDUSTRY TRENDS RELATED TO COVID-19
5.4 GLOBAL REGULATORY SCENARIO
5.5 ECOSYSTEM: PARENT MARKET
5.6 PORTER’S FIVE FORCES ANALYSIS
5.6.1 DEGREE OF COMPETITION
5.6.2 BARGAINING POWER OF SUPPLIERS
5.6.3 BARGAINING POWER OF BUYERS
5.6.4 THREAT OF NEW ENTRANTS
5.6.5 THREAT OF SUBSTITUTES
6 PCR TECHNOLOGIES MARKET, BY TECHNIQUE (Page No. - 48)
6.1 INTRODUCTION
6.2 CONVENTIONAL PCR
6.2.1 HIGH ADOPTION OF THIS TECHNIQUE AND ITS DIVERSE APPLICATIONS TO SUSTAIN MARKET GROWTH
6.3 REAL-TIME PCR
6.3.1 GROWING ADOPTION AMONG RESEARCHERS AND HEALTHCARE PROFESSIONALS TO FUEL MARKET GROWTH
6.4 DIGITAL PCR
6.4.1 ONGOING TECHNOLOGICAL DEVELOPMENTS WITH RESPECT TO DIGITAL PCR TO DRIVE MARKET GROWTH
6.5 REVERSE TRANSCRIPTION PCR
6.5.1 HIGHER SENSITIVITY FOR MRNA DETECTION IS A MAJOR CONTRIBUTING FACTOR TO MARKET GROWTH
6.6 HOT-START PCR
6.6.1 HASSLE-FREE SETUP OF SAMPLES IS A KEY ADVANTAGE OFFERED BY THIS TECHNIQUE
6.7 MULTIPLEX PCR
6.7.1 COST-EFFECTIVENESS OF THIS TECHNIQUE TO DRIVE MARKET GROWTH
6.8 OTHER PCR TECHNIQUES
7 PCR TECHNOLOGIES MARKET, BY PRODUCT TYPE (Page No. - 67)
7.1 INTRODUCTION
7.2 INSTRUMENTS
7.2.1 INCREASING AVAILABILITY OF INNOVATIVE PCR INSTRUMENTS WILL DRIVE MARKET GROWTH
7.3 REAGENTS AND CONSUMABLES
7.3.1 INCREASING NUMBER OF ANALYTICAL PROCEDURES AMONG RESEARCHERS TO FUEL MARKET GROWTH
7.4 SOFTWARE AND SERVICES
7.4.1 AUTOMATION AND DIGITALIZATION OF LABORATORY PROCESSES TO FUEL ADOPTION AMONG END USERS
8 PCR TECHNOLOGIES MARKET, BY APPLICATION (Page No. - 72)
8.1 INTRODUCTION
8.2 GENE EXPRESSION ANALYSIS
8.2.1 GENE EXPRESSION ANALYSIS IS USED IN EPIGENETICS, SIRNA QUANTIFICATION, MRNA ANALYSIS, AND CELL LINE VALIDATION
8.3 GENETIC SEQUENCING
8.3.1 REDUCED COST OF SEQUENCING TO DRIVE MARKET GROWTH
8.4 GENOTYPING
8.4.1 SNP GENOTYPING CAN ACCELERATE THE ERA OF PERSONALIZED MEDICINE
8.5 NUCLEIC ACID DETECTION
8.5.1 PCR TECHNIQUES HAVE WIDE APPLICATIONS IN NUCLEIC ACID DETECTION
8.6 NUCLEIC ACID SYNTHESIS
8.6.1 DNA SYNTHESIS HAS OPENED AVENUES FOR PROGRESS IN BIOLOGY
8.7 STANDARD VALIDATION/VERIFICATION
8.7.1 PCR TECHNIQUES ARE USED FOR REGIONAL/GLOBAL VALIDATION TO FRAME COMMERCIAL/NON-COMMERCIAL GUIDELINES
8.8 DIAGNOSTIC APPLICATIONS
8.8.1 DIAGNOSTIC APPLICATIONS SEGMENT ACCOUNTED FOR THE LARGEST SHARE OF THE MARKET
8.9 ENVIRONMENTAL APPLICATIONS
8.9.1 PCR IS THE MOST SENSITIVE TECHNIQUE TO DETECT PATHOGENS IN ENVIRONMENTAL SAMPLES
8.10 OTHER APPLICATIONS
9 PCR TECHNOLOGIES MARKET, BY END USER (Page No. - 82)
9.1 INTRODUCTION
9.2 HOSPITALS AND DIAGNOSTIC CENTERS
9.2.1 HIGH PREVALENCE OF TARGET DISEASES TO DRIVE MARKET GROWTH
9.3 HEALTHCARE INDUSTRY
9.3.1 PCR HAS WIDE APPLICATIONS IN THE HEALTHCARE INDUSTRY
9.4 ACADEMIA AND GOVERNMENT ORGANIZATIONS
9.4.1 AVAILABILITY OF COST-EFFECTIVE AND INNOVATIVE PCR PRODUCTS TO DRIVE ADOPTION
9.5 PHARMA-BIOTECH COMPANIES
9.5.1 INCREASING R&D INITIATIVES BY PHARMA-BIOTECH COMPANIES TO FUEL THE ADOPTION OF PCR TECHNOLOGIES
9.6 APPLIED INDUSTRIES
9.6.1 INCREASING ENVIRONMENTAL REGULATIONS TO DRIVE THE ADOPTION OF PCR TECHNIQUES
9.7 OTHER END USERS
10 PCR TECHNOLOGIES MARKET, BY REGION (Page No. - 90)
10.1 INTRODUCTION
10.2 NORTH AMERICA
10.2.1 US
10.2.1.1 Growing adoption of PCR techniques in research & academia to drive market growth
10.2.2 CANADA
10.2.2.1 Government initiatives for supporting genomics research to drive market growth in Canada
10.3 EUROPE
10.3.1 GERMANY
10.3.1.1 Large-scale outsourcing of clinical diagnostic testing by hospitals to drive market growth
10.3.2 UK
10.3.2.1 Growing focus on genomics research to support market growth in the UK
10.3.3 FRANCE
10.3.3.1 Initiatives for developing genomic medicine to support market growth in France
10.3.4 ITALY
10.3.4.1 Increasing R&D investments by pharmaceutical companies to propel market growth
10.3.5 SPAIN
10.3.5.1 Increasing prevalence of chronic and infectious diseases to drive market growth
10.3.6 REST OF EUROPE
10.4 ASIA PACIFIC
10.4.1 JAPAN
10.4.1.1 Strong research and healthcare infrastructure to support market growth in Japan
10.4.2 CHINA
10.4.2.1 Healthcare infrastructure modernization to support market growth in China
10.4.3 INDIA
10.4.3.1 Presence of a large target patient population to support market growth in India
10.4.4 AUSTRALIA
10.4.4.1 High healthcare expenditure in the country to support market growth
10.4.5 SOUTH KOREA
10.4.5.1 Growing number of private hospitals and independent testing laboratories to drive market growth
10.4.6 REST OF ASIA PACIFIC
10.5 LATIN AMERICA
10.5.1 BRAZIL
10.5.1.1 Brazil is expected to dominate the LATAM market
10.5.2 MEXICO
10.5.2.1 Favorable trade agreements will support imports and improve the accessibility to PCR instruments in Mexico
10.5.3 REST OF LATIN AMERICA
10.6 MIDDLE EAST AND AFRICA
10.6.1 LOW PURCHASING POWER OF END USERS AND INFRASTRUCTURAL LIMITATIONS TO RESTRAIN MARKET GROWTH IN THE MEA
11 COMPETITIVE LANDSCAPE (Page No. - 121)
11.1 OVERVIEW
11.2 GLOBAL MARKET SHARE ANALYSIS
11.2.1 GLOBAL PCR TECHNOLOGIES MARKET SHARE ANALYSIS (2019)
11.3 COMPETITIVE LEADERSHIP MAPPING
11.3.1 STARS
11.3.2 EMERGING LEADERS
11.3.3 PERVASIVE
11.3.4 PARTICIPANTS
11.4 COMPETITIVE SCENARIO
12 COMPANY PROFILES (Page No. - 129)
12.1 KEY PLAYERS
12.1.1 THERMO FISHER SCIENTIFIC, INC.
12.1.1.1 Products & services offered
12.1.1.2 Recent developments
12.1.1.3 MnM view
12.1.2 F. HOFFMAN-LA ROCHE LTD.
12.1.2.1 Products & services offered
12.1.2.2 Recent developments
12.1.3 BIO-RAD LABORATORIES, INC.
12.1.3.1 Products & services offered
12.1.3.2 Recent developments
12.1.3.3 MnM view
12.1.4 QIAGEN N.V.
12.1.4.1 Products offered
12.1.4.2 Recent developments
12.1.5 TAKARA BIO, INC.
12.1.5.1 Products offered
12.1.5.2 Recent developments
12.1.6 AGILENT TECHNOLOGIES, INC.
12.1.6.1 Products offered
12.1.6.2 Recent developments
12.1.7 BIOMÉRIEUX S.A.
12.1.7.1 Products offered
12.1.7.2 Recent developments
12.1.8 FLUIDIGM CORPORATION
12.1.8.1 Products offered
12.1.8.2 Recent developments
12.1.9 DANAHER CORPORATION
12.1.9.1 Products offered
12.1.9.2 Recent developments
12.1.10 ABBOTT LABORATORIES
12.1.10.1 Products offered
12.1.10.2 Recent developments
12.2 OTHER PLAYERS
12.2.1 MERCK KGAA
12.2.1.1 Products & services offered
12.2.1.2 Recent developments
12.2.2 BECTON, DICKINSON AND COMPANY
12.2.2.1 Products offered
12.2.2.2 Recent developments
12.2.3 PROMEGA CORPORATION
12.2.3.1 Products offered
12.2.3.2 Recent developments
12.2.4 EPPENDORF AG
12.2.4.1 Products offered
12.2.4.2 Recent developments
12.2.5 ANALYTIK JENA AG (A WHOLLY OWNED SUBSIDIARY OF ENDRESS+HAUSER AG)
12.2.5.1 Products offered
13 APPENDIX (Page No. - 184)
13.1 DISCUSSION GUIDE
13.2 KNOWLEDGE STORE: MARKETSANDMARKETS’ SUBSCRIPTION PORTAL
13.3 AVAILABLE CUSTOMIZATIONS
13.4 RELATED REPORTS
13.5 AUTHOR DETAILS
LIST OF TABLES (126 TABLES)
TABLE 1 PCR TECHNOLOGIES MARKET, BY TECHNIQUE, 2018–2025 (USD MILLION)
TABLE 2 CONVENTIONAL PCR MARKET, BY REGION, 2018–2025 (USD MILLION)
TABLE 3 CONVENTIONAL PCR MARKET, BY PRODUCT TYPE, 2018–2025 (USD MILLION)
TABLE 4 CONVENTIONAL PCR MARKET, BY APPLICATION, 2018–2025 (USD MILLION)
TABLE 5 CONVENTIONAL PCR MARKET, BY END USER, 2018–2025 (USD MILLION)
TABLE 6 REAL-TIME PCR MARKET, BY REGION, 2018–2025 (USD MILLION)
TABLE 7 REAL-TIME PCR MARKET, BY PRODUCT TYPE, 2018–2025 (USD MILLION)
TABLE 8 REAL-TIME PCR MARKET, BY APPLICATION, 2018–2025 (USD MILLION)
TABLE 9 REAL-TIME PCR MARKET, BY END USER, 2018–2025 (USD MILLION)
TABLE 10 DIGITAL PCR MARKET, BY REGION, 2018–2025 (USD MILLION)
TABLE 11 DIGITAL PCR MARKET, BY PRODUCT TYPE, 2018–2025 (USD MILLION)
TABLE 12 DIGITAL PCR MARKET, BY APPLICATION, 2018–2025 (USD MILLION)
TABLE 13 DIGITAL PCR MARKET, BY END USER, 2018–2025 (USD MILLION)
TABLE 14 REVERSE TRANSCRIPTION PCR MARKET, BY REGION, 2018–2025 (USD MILLION)
TABLE 15 REVERSE TRANSCRIPTION PCR MARKET, BY PRODUCT TYPE, 2018–2025 (USD MILLION)
TABLE 16 REVERSE TRANSCRIPTION PCR MARKET, BY APPLICATION, 2018–2025 (USD MILLION)
TABLE 17 REVERSE TRANSCRIPTION PCR MARKET, BY END USER, 2018–2025 (USD MILLION)
TABLE 18 HOT-START PCR MARKET, BY REGION, 2018–2025 (USD MILLION)
TABLE 19 HOT-START PCR MARKET, BY PRODUCT TYPE, 2018–2025 (USD MILLION)
TABLE 20 HOT-START PCR MARKET, BY APPLICATION, 2018–2025 (USD MILLION)
TABLE 21 HOT-START PCR MARKET, BY END USER, 2018–2025 (USD MILLION)
TABLE 22 MULTIPLEX PCR MARKET, BY REGION, 2018–2025 (USD MILLION)
TABLE 23 MULTIPLEX PCR MARKET, BY PRODUCT TYPE, 2018–2025 (USD MILLION)
TABLE 24 MULTIPLEX PCR MARKET, BY APPLICATION, 2018–2025 (USD MILLION)
TABLE 25 MULTIPLEX PCR MARKET, BY END USER, 2018–2025 (USD MILLION)
TABLE 26 OTHER PCR TECHNIQUES MARKET, BY REGION, 2018–2025 (USD MILLION)
TABLE 27 OTHER PCR TECHNIQUES MARKET, BY PRODUCT TYPE, 2018–2025 (USD MILLION)
TABLE 28 OTHER PCR TECHNIQUES MARKET, BY APPLICATION, 2018–2025 (USD MILLION)
TABLE 29 OTHER PCR TECHNIQUES MARKET, BY END USER, 2018–2025 (USD MILLION)
TABLE 30 PCR TECHNOLOGIES MARKET, BY PRODUCT TYPE, 2018–2025 (USD MILLION)
TABLE 31 PCR INSTRUMENTS MARKET, BY REGION, 2018–2025 (USD MILLION)
TABLE 32 PCR REAGENTS AND CONSUMABLES MARKET, BY REGION, 2018–2025 (USD MILLION)
TABLE 33 PCR SOFTWARE AND SERVICES MARKET, BY REGION, 2018–2025 (USD MILLION)
TABLE 34 PCR TECHNOLOGIES MARKET, BY APPLICATION, 2018–2025 (USD MILLION)
TABLE 35 PCR TECHNOLOGIES MARKET FOR GENE EXPRESSION ANALYSIS, BY REGION, 2018–2025 (USD MILLION)
TABLE 36 PCR TECHNOLOGIES MARKET FOR GENETIC SEQUENCING, BY REGION, 2018–2025 (USD MILLION)
TABLE 37 PCR TECHNOLOGIES MARKET FOR GENOTYPING, BY REGION, 2018–2025 (USD MILLION)
TABLE 38 PCR TECHNOLOGIES MARKET FOR NUCLEIC ACID DETECTION, BY REGION, 2018–2025 (USD MILLION)
TABLE 39 PCR TECHNOLOGIES MARKET FOR NUCLEIC ACID SYNTHESIS, BY REGION, 2018–2025 (USD MILLION)
TABLE 40 PCR TECHNOLOGIES MARKET FOR STANDARD VALIDATION/VERIFICATION, BY REGION, 2018–2025 (USD MILLION)
TABLE 41 PCR TECHNOLOGIES MARKET FOR DIAGNOSTIC APPLICATIONS, BY REGION, 2018–2025 (USD MILLION)
TABLE 42 PCR TECHNOLOGIES MARKET FOR ENVIRONMENTAL APPLICATIONS, BY REGION, 2018–2025 (USD MILLION)
TABLE 43 PCR TECHNOLOGIES MARKET FOR OTHER APPLICATIONS, BY REGION, 2018–2025 (USD MILLION)
TABLE 44 PCR TECHNOLOGIES MARKET, BY END USER, 2018–2025 (USD MILLION)
TABLE 45 PCR TECHNOLOGIES MARKET FOR HOSPITALS AND DIAGNOSTIC CENTERS, BY REGION, 2018–2025 (USD MILLION)
TABLE 46 PCR TECHNOLOGIES MARKET FOR HEALTHCARE INDUSTRY, BY REGION, 2018–2025 (USD MILLION)
TABLE 47 PCR TECHNOLOGIES MARKET FOR ACADEMIA AND GOVERNMENT ORGANIZATIONS, BY REGION, 2018–2025 (USD MILLION)
TABLE 48 PCR TECHNOLOGIES MARKET FOR PHARMA-BIOTECH COMPANIES, BY REGION, 2018–2025 (USD MILLION)
TABLE 49 PCR TECHNOLOGIES MARKET FOR APPLIED INDUSTRIES, BY REGION, 2018–2025 (USD MILLION)
TABLE 50 PCR TECHNOLOGIES MARKET FOR OTHER END USERS, BY REGION, 2018–2025 (USD MILLION)
TABLE 51 PCR TECHNOLOGIES MARKET, BY REGION, 2018–2025 (USD MILLION)
TABLE 52 NORTH AMERICA: PCR TECHNOLOGIES MARKET, BY COUNTRY, 2018–2025 (USD MILLION)
TABLE 53 NORTH AMERICA: PCR TECHNOLOGIES MARKET, BY TECHNIQUE, 2018–2025 (USD MILLION)
TABLE 54 NORTH AMERICA: PCR TECHNOLOGIES MARKET, BY PRODUCT TYPE, 2018–2025 (USD MILLION)
TABLE 55 NORTH AMERICA: PCR TECHNOLOGIES MARKET, BY END USER, 2018–2025 (USD MILLION)
TABLE 56 US: PCR TECHNOLOGIES MARKET, BY TECHNIQUE, 2018–2025 (USD MILLION)
TABLE 57 CANADA: PCR TECHNOLOGIES MARKET, BY TECHNIQUE, 2018–2025 (USD MILLION)
TABLE 58 EUROPE: PCR TECHNOLOGIES MARKET, BY COUNTRY, 2018–2025 (USD MILLION)
TABLE 59 EUROPE: PCR TECHNOLOGIES MARKET, BY TECHNIQUE, 2018–2025 (USD MILLION)
TABLE 60 EUROPE: PCR TECHNOLOGIES MARKET, BY PRODUCT TYPE, 2018–2025 (USD MILLION)
TABLE 61 EUROPE: PCR TECHNOLOGIES MARKET, BY END USER, 2018–2025 (USD MILLION)
TABLE 62 GERMANY: PCR TECHNOLOGIES MARKET, BY TECHNIQUE, 2018–2025 (USD MILLION)
TABLE 63 UK: PCR TECHNOLOGIES MARKET, BY TECHNIQUE, 2018–2025 (USD MILLION)
TABLE 64 FRANCE: PCR TECHNOLOGIES MARKET, BY TECHNIQUE, 2018–2025 (USD MILLION)
TABLE 65 ITALY: PCR TECHNOLOGIES MARKET, BY TECHNIQUE, 2018–2025 (USD MILLION)
TABLE 66 SPAIN: PCR TECHNOLOGIES MARKET, BY TECHNIQUE, 2018–2025 (USD MILLION)
TABLE 67 REST OF EUROPE: PCR TECHNOLOGIES MARKET, BY TECHNIQUE, 2018–2025 (USD MILLION)
TABLE 68 ASIA PACIFIC: PCR TECHNOLOGIES MARKET, BY COUNTRY, 2018–2025 (USD MILLION)
TABLE 69 ASIA PACIFIC: PCR TECHNOLOGIES MARKET, BY TECHNIQUE, 2018–2025 (USD MILLION)
TABLE 70 ASIA PACIFIC: PCR TECHNOLOGIES MARKET, BY PRODUCT TYPE, 2018–2025 (USD MILLION)
TABLE 71 ASIA PACIFIC: PCR TECHNOLOGIES MARKET, BY END USER, 2018–2025 (USD MILLION)
TABLE 72 JAPAN: PCR TECHNOLOGIES MARKET, BY TECHNIQUE, 2018–2025 (USD MILLION)
TABLE 73 CHINA: PCR TECHNOLOGIES MARKET, BY TECHNIQUE, 2018–2025 (USD MILLION)
TABLE 74 INDIA: PCR TECHNOLOGIES MARKET, BY TECHNIQUE, 2018–2025 (USD MILLION)
TABLE 75 AUSTRALIA: PCR TECHNOLOGIES MARKET, BY TECHNIQUE, 2018–2025 (USD MILLION)
TABLE 76 SOUTH KOREA: PCR TECHNOLOGIES MARKET, BY TECHNIQUE, 2018–2025 (USD MILLION)
TABLE 77 REST OF ASIA PACIFIC: PCR TECHNOLOGIES MARKET, BY TECHNIQUE, 2018–2025 (USD MILLION)
TABLE 78 LATIN AMERICA: PCR TECHNOLOGIES MARKET, BY COUNTRY, 2018–2025 (USD MILLION)
TABLE 79 LATIN AMERICA: PCR TECHNOLOGIES MARKET, BY TECHNIQUE, 2018–2025 (USD MILLION)
TABLE 80 LATIN AMERICA: PCR TECHNOLOGIES MARKET, BY PRODUCT TYPE, 2018–2025 (USD MILLION)
TABLE 81 LATIN AMERICA: PCR TECHNOLOGIES MARKET, BY END USER, 2018–2025 (USD MILLION)
TABLE 82 BRAZIL: PCR TECHNOLOGIES MARKET, BY TECHNIQUE, 2018–2025 (USD MILLION)
TABLE 83 MEXICO: PCR TECHNOLOGIES MARKET, BY TECHNIQUE, 2018–2025 (USD MILLION)
TABLE 84 REST OF LATIN AMERICA: PCR TECHNOLOGIES MARKET, BY TECHNIQUE, 2018–2025 (USD MILLION)
TABLE 85 MIDDLE EAST & AFRICA: PCR TECHNOLOGIES MARKET, BY TECHNIQUE, 2018–2025 (USD MILLION)
TABLE 86 MIDDLE EAST & AFRICA: PCR TECHNOLOGIES MARKET, BY PRODUCT TYPE, 2018–2025 (USD MILLION)
TABLE 87 MIDDLE EAST & AFRICA: PCR TECHNOLOGIES MARKET, BY END USER, 2018–2025 (USD MILLION)
TABLE 88 PCR TECHNOLOGIES MARKET: PRODUCT LAUNCHES AND APPROVALS, 2017–2020
TABLE 89 PCR TECHNOLOGIES MARKET: EXPANSIONS, 2017–2020
TABLE 90 PCR TECHNOLOGIES MARKET: ACQUISITIONS, 2017–2020
TABLE 91 THERMO FISHER SCIENTIFIC, INC.: BUSINESS OVERVIEW
TABLE 92 THERMO FISHER SCIENTIFIC, INC.: PRODUCTS & SERVICES OFFERED
TABLE 93 F. HOFFMAN-LA ROCHE LTD.: BUSINESS OVERVIEW
TABLE 94 EXCHANGE RATES (UTILIZED FOR CONVERSION OF CHF TO USD)
TABLE 95 ROCHE DIAGNOSTICS: PRODUCTS & SERVICES OFFERED
TABLE 96 BIO-RAD LABORATORIES, INC.: BUSINESS OVERVIEW
TABLE 97 BIO-RAD LABORATORIES, INC.: PRODUCTS AND SERVICES OFFERED
TABLE 98 QIAGEN N.V.: BUSINESS OVERVIEW
TABLE 99 QIAGEN N.V.: PRODUCTS OFFERED
TABLE 100 TAKARA BIO, INC.: BUSINESS OVERVIEW
TABLE 101 EXCHANGE RATES (UTILIZED FOR CONVERSION OF JPY TO USD)
TABLE 102 TAKARA BIO, INC.: PRODUCTS OFFERED
TABLE 103 AGILENT TECHNOLOGIES, INC.: BUSINESS OVERVIEW
TABLE 104 AGILENT TECHNOLOGIES, INC.: PRODUCTS OFFERED
TABLE 105 BIOMÉRIEUX S.A.: BUSINESS OVERVIEW
TABLE 106 EXCHANGE RATES (UTILIZED FOR CONVERSION OF EUR TO USD)
TABLE 107 BIOMÉRIEUX: PRODUCTS OFFERED
TABLE 108 FLUIDIGM CORPORATION: BUSINESS OVERVIEW
TABLE 109 FLUIDIGM CORPORATION: PRODUCTS OFFERED
TABLE 110 DANAHER CORPORATION: BUSINESS OVERVIEW
TABLE 111 DANAHER CORPORATION: PRODUCTS OFFERED
TABLE 112 ABBOTT LABORATORIES: BUSINESS OVERVIEW
TABLE 113 ABBOTT LABORATORIES: PRODUCTS OFFERED
TABLE 114 MERCK KGAA: BUSINESS OVERVIEW
TABLE 115 EXCHANGE RATES (UTILIZED FOR CONVERSION OF EUR TO USD)
TABLE 116 MERCK KGAA: PRODUCTS & SERVICES OFFERED
TABLE 117 BECTON, DICKINSON AND COMPANY: BUSINESS OVERVIEW
TABLE 118 BECTON, DICKINSON AND COMPANY: PRODUCTS OFFERED
TABLE 119 PROMEGA CORPORATION: BUSINESS OVERVIEW
TABLE 120 PROMEGA CORPORATION: PRODUCTS OFFERED
TABLE 121 EPPENDORF AG: BUSINESS OVERVIEW
TABLE 122 EXCHANGE RATES (UTILIZED FOR THE CONVERSION OF EUR TO USD)
TABLE 123 EPPENDORF AG: PRODUCTS OFFERED
TABLE 124 ENDRESS+HAUSER: BUSINESS OVERVIEW
TABLE 125 EXCHANGE RATES (UTILIZED FOR CONVERSION OF EUR TO USD)
TABLE 126 ANALYTIK JENA AG: PRODUCTS OFFERED
LIST OF FIGURES (37 FIGURES)
FIGURE 1 RESEARCH DESIGN
FIGURE 2 BREAKDOWN OF PRIMARIES: PCR TECHNOLOGIES MARKET
FIGURE 3 RESEARCH METHODOLOGY: HYPOTHESIS BUILDING
FIGURE 4 MARKET SIZE ESTIMATION METHODOLOGY: GLOBAL PCR TECHNOLOGIES MARKET
FIGURE 5 DATA TRIANGULATION
FIGURE 6 PCR TECHNOLOGIES MARKET, BY PRODUCT TYPE, 2020 VS. 2025 (USD MILLION)
FIGURE 7 PCR TECHNOLOGIES MARKET, BY TECHNIQUE, 2020 VS. 2025 (USD MILLION)
FIGURE 8 PCR TECHNOLOGIES MARKET, BY END USER, 2020 VS. 2025 (USD MILLION)
FIGURE 9 APAC MARKET TO GROW AT THE HIGHEST RATE DURING THE FORECAST PERIOD
FIGURE 10 RISING INCIDENCE OF TARGET INFECTIOUS DISEASES AND GENETIC DISORDERS IS EXPECTED TO DRIVE MARKET GROWTH
FIGURE 11 REAL-TIME PCR SEGMENT ACCOUNTED FOR THE LARGEST SHARE OF THE GLOBAL PCR TECHNOLOGIES MARKETS IN 2020
FIGURE 12 DIAGNOSTIC APPLICATIONS SEGMENT TO DOMINATE THE MARKET DURING THE FORECAST PERIOD
FIGURE 13 APAC MARKET TO REGISTER THE HIGHEST GROWTH RATE DURING THE FORECAST PERIOD
FIGURE 14 PCR TECHNOLOGIES MARKET: DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES
FIGURE 15 GLOBAL BURDEN OF HIV INFECTIONS, BY REGION, 2017
FIGURE 16 GROWING GERIATRIC POPULATION ACROSS KEY GEOGRAPHIES, 2019 VS. 2050 (MILLION)
FIGURE 17 TRADITIONAL PCR VS. QPCR AND DPCR
FIGURE 18 NORTH AMERICA: PCR TECHNOLOGIES MARKET SNAPSHOT
FIGURE 19 ASIA PACIFIC: PCR TECHNOLOGIES MARKET SNAPSHOT
FIGURE 20 KEY DEVELOPMENTS BY LEADING PLAYERS IN THE PCR TECHNOLOGIES MARKET, 2017–2020
FIGURE 21 GLOBAL PCR TECHNOLOGIES MARKET SHARE ANALYSIS, BY KEY PLAYER (2019)
FIGURE 22 PCR TECHNOLOGIES MARKET: COMPETITIVE LEADERSHIP MAPPING (2019)
FIGURE 23 PCR TECHNOLOGIES MARKET: COMPETITIVE LEADERSHIP MAPPING (SME/START-UPS)
FIGURE 24 THERMO FISHER SCIENTIFIC, INC.: COMPANY SNAPSHOT (2019)
FIGURE 25 ROCHE DIAGNOSTICS: COMPANY SNAPSHOT (2019)
FIGURE 26 BIO-RAD LABORATORIES, INC.: COMPANY SNAPSHOT (2019)
FIGURE 27 QIAGEN N.V.: COMPANY SNAPSHOT (2019)
FIGURE 28 TAKARA BIO, INC.: COMPANY SNAPSHOT (2019)
FIGURE 29 AGILENT TECHNOLOGIES, INC.: COMPANY SNAPSHOT (2019)
FIGURE 30 BIOMÉRIEUX S.A.: COMPANY SNAPSHOT (2019)
FIGURE 31 FLUIDIGM CORPORATION: COMPANY SNAPSHOT (2019)
FIGURE 32 DANAHER CORPORATION: COMPANY SNAPSHOT (2019)
FIGURE 33 ABBOTT LABORATORIES: COMPANY SNAPSHOT (2019)
FIGURE 34 MERCK KGAA: COMPANY SNAPSHOT (2019)
FIGURE 35 BECTON, DICKINSON AND COMPANY: COMPANY SNAPSHOT (2019)
FIGURE 36 EPPENDORF AG: COMPANY SNAPSHOT (2019)
FIGURE 37 ENDRESS+HAUSER AG: COMPANY SNAPSHOT (2019)
The study involved four major activities in estimating the current size of the PCR technologies market. Exhaustive secondary research was done to collect information on the market and its different subsegments. The next step was to validate these findings, assumptions, and sizing with industry experts across the value chain through primary research. Both top-down and bottom-up approaches were employed to estimate the complete market size. Thereafter, market breakdown and data triangulation procedures were used to estimate the size of the segments and subsegments.
Secondary Research
In the secondary research process, various secondary sources such as annual reports, press releases & investor presentations of companies, white papers, certified publications, articles by recognized authors, gold-standard & silver-standard websites, regulatory bodies, and databases (such as D&B Hoovers, Bloomberg Business, and Factiva) were referred to in order to identify and collect information for this study.
Primary Research
Extensive primary research was conducted after acquiring knowledge about the PCR technologies market scenario through secondary research. A significant number of primary interviews were conducted from both the demand (healthcare providers, research institutes, and healthcare professionals) and supply sides (developers, manufacturers, and distributors of PCR technologies products). The primaries interviewed for this study include experts from the PCR technologies products industry (such as CEOs, VPs, directors, sales heads, and marketing managers of tier 1, 2, and 3 companies engaged in offering PCR technologies products and services across the globe) and administrators & purchase managers of hospitals CROs, research institutes, academia, and pharma and biotech companies.
The following is a breakdown of primary respondents:
To know about the assumptions considered for the study, download the pdf brochure
Market Size Estimation
A detailed market estimation approach was followed to estimate and validate the size of the PCR technologies market and other dependent submarkets, as mentioned above. The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. The research methodology includes the study of the annual and quarterly financial reports of the top market players as well as interviews with industry experts for key insights (both quantitative and qualitative trends) on the PCR technologies market. All possible parameters that affect the market segments covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data. This data was consolidated and added to detailed inputs and analysis from MarketsandMarkets and presented in this report. The research methodology used to estimate the market size includes the following:
- The key players in the industry and markets have been identified through extensive secondary research.
- The industry’s supply chain and market size, in terms of value, have been determined through primary and secondary research processes.
- All percentage shares, splits, and breakdowns have been determined using secondary sources and verified through primary sources.
To know about the assumptions considered for the study, Request for Free Sample Report
Data Triangulation
After arriving at the overall market size of the PCR technologies industry from the market estimation approach explained above, the global market was split into several segments and subsegments. To complete the overall market engineering process and arrive at the exact market value data, data triangulation and market breakdown methodology methods were employed, wherever applicable. The data was triangulated by studying various factors and trends from both the demand and supply sides.
Report Objectives
- To define, describe, and forecast the global PCR technologies market on the basis of technique, product, application, end user, and region
- To provide detailed information on the major factors influencing market growth (such as drivers, restraints, opportunities, and industry-specific challenges)
- To strategically analyze micromarkets in terms of individual growth trends, future prospects, and contributions to the overall PCR technologies market
- To analyze opportunities in the global PCR technologies market for major stakeholders and detail the competitive landscape for market leaders
- To forecast the size of market segments with respect to the five major regions, namely, North America, Europe, Asia Pacific, Latin America, and the Middle East and Africa
- To profile key players and comprehensively analyze their market shares and core competencies
- To track and analyze competitive developments such as product developments; mergers & acquisitions; expansions; and partnerships, collaborations, & agreements
Available Customizations
With the given market data, MarketsandMarkets offers customizations as per the company’s specific needs. The following customization options are available for the global PCR technologies market report:
Product Analysis
- Product matrix, which gives a detailed comparison of the product portfolios of the top five companies
Company Information
- Detailed analysis and profiling of additional market players (up to 5)
Get in-depth analysis of the COVID-19 impact on the PCR Technologies Market
Benchmarking the rapid strategy shifts of the Top 100 companies in the PCR Technologies Market
Request For Special Pricing
- Triangulate with your Own Data
- Get Data as per your Format and Definition
- Gain a Deeper Dive on a Specific Application, Geography, Customer or Competitor
- Any level of Personalization
- What are the Known and Unknown Adjacencies Impacting the PCR Technologies Market
- What will your New Revenue Sources be?
- Who will be your Top Customer; what will make them switch?
- Defend your Market Share or Win Competitors
- Get a Scorecard for Target Partners
Growth opportunities and latent adjacency in PCR Technologies Market